Enanta Pharmaceuticals Inc (ENTA) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Enanta Pharmaceuticals Inc stock $8.85, price $10.67, that is 17.1% below the price, quality 24 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Enanta Pharmaceuticals Inc
ENTA · USExpensive (fair value 17% below the price), weak company and price moving sideways: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $4.26 – $97.37 · fair‑value band $6.64 – $11.07 · the $10.67 price screens above the $8.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Enanta Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications.
Show moreShow less
The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Stock analysis
Enanta Pharmaceuticals Inc (ENTA) currently trades at $10.67, while our estimate is $8.85, 17% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $6.64 (bear) to $11.07 (bull), the price of $10.67 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Enanta Pharmaceuticals Inc reported revenue of $65.3M in FY2025 versus $97.1M in FY2021, a compound −9.4%/yr. Reported net income was −$81.9M in FY2025.
Key figures
Market cap $310M Small · P/S ratio 4.75 · EPS (TTM) $−2.42 · Net margin −96.9% · Return on equity −70.1% · Return on assets (EBIT) −30.0% (5-year average) · Operating margin −120% · Revenue (TTM) $65.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −17%, ENTA screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- SaleJay R. LulyPresident and CEO, Director4,743 shares at $14.23$67,493Dec 5, 2025
- SaleYat Sun OrChief Scientific Officer2,390 shares at $14.23$34,010Dec 5, 2025
- SaleTara Lynn KiefferChief Product Strategy Officer2,106 shares at $14.23$29,968Dec 5, 2025
- SaleBrendan LuuChief Business Officer1,394 shares at $14.23$19,837Dec 5, 2025
- SaleScott T. RottinghausChief Medical Officer798 shares at $14.23$11,356Dec 5, 2025
- SaleHarry R. Trout IIIOfficer2× since Dec 2, 2025: 922 shares, avg. $14.12$13,017Dec 5, 2025
- SaleKathleen S. CappsOfficer2× since Dec 2, 2025: 530 shares, avg. $14.12$7,486Dec 5, 2025
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Enanta Pharmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs ENTA |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs ENTA |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs ENTA |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs ENTA |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs ENTA |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs ENTA |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs ENTA |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs ENTA |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs ENTA |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs ENTA |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Enanta Pharmaceuticals Inc (ENTA) overvalued or undervalued?
What is the fair value of ENTA?
What is the quality score of ENTA?
What is the price target for Enanta Pharmaceuticals Inc (ENTA)?
What is the Enanta Pharmaceuticals Inc stock forecast for 2026?
What is the revenue of Enanta Pharmaceuticals Inc (ENTA)?
What is the intrinsic value of Enanta Pharmaceuticals Inc (ENTA)?
Is Enanta Pharmaceuticals Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of ENTA?
How much is Enanta Pharmaceuticals Inc worth?
What do the bullish and bearish scenarios say about ENTA?
How solid is the balance sheet of Enanta Pharmaceuticals Inc (ENTA)?
How far is ENTA from its 52-week high?
Which stocks are comparable to Enanta Pharmaceuticals Inc?
Is Enanta Pharmaceuticals Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Enanta Pharmaceuticals Inc (ENTA)?
What should I pay attention to with Enanta Pharmaceuticals Inc right now?
Key figures of Enanta Pharmaceuticals Inc
How large is the market capitalisation of Enanta Pharmaceuticals Inc (ENTA)?
What is the P/S ratio of Enanta Pharmaceuticals Inc (ENTA)?
What are the earnings per share of Enanta Pharmaceuticals Inc (ENTA)?
What is the net margin of Enanta Pharmaceuticals Inc (ENTA)?
What is the return on equity of Enanta Pharmaceuticals Inc (ENTA)?
What is the EBIT return on assets of Enanta Pharmaceuticals Inc (ENTA)?
What is the operating margin of Enanta Pharmaceuticals Inc (ENTA)?
How fast is revenue growing at Enanta Pharmaceuticals Inc (ENTA)?
How fast are earnings growing at Enanta Pharmaceuticals Inc (ENTA)?
How much free cash flow does Enanta Pharmaceuticals Inc (ENTA) generate?
How much net debt does Enanta Pharmaceuticals Inc (ENTA) carry?
Watch Enanta Pharmaceuticals Inc in the live analysis
One click puts Enanta Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.